Illicit Drug Use

Resource Center

FDA Alerts

FDA Alert

FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose

08/23/2024

Anthony Calabro, MA

The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.

08/23/2024

Research Summaries

Research Summary

Can Increasing Follow-up After Patients With Hepatitis C Achieve Sustained Virologic Response Reduce Reinfection Rates?

10/16/2024

Miranda Manier, BA

In a cohort study, researchers observed a significant decrease in incident reinfection among patients with Hepatitis C who received increased follow-up after achieving sustained virologic response.

10/16/2024

FDA Alert

FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose

08/23/2024

Anthony Calabro, MA

The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.

08/23/2024

Research Summary

Prevalence of Hepatitis C Among Pregnant Women Increased 16-Fold From 1998-2018

10/18/2023

Jessica Ganga

Researchers sought to find an association and prevalence of hepatitis C infection during pregnancy using data from 1998 to 2018.

10/18/2023

drug use

CDC: Tianeptine Could Be An Emerging Public Health Risk

08/03/2018

Following study results showing that tianeptine is an opioid receptor agonist, as well as several case reports of severe adverse effects with use of the agent, the CDC sought to characterize tianeptine...

08/03/2018

drug use

Users of Generic Blood Pressure Drugs May Experience More Adverse Events

10/04/2017

Few studies have evaluated outcomes following generic drug commercialization at the population level. Using a cohort of over 135,000 individuals, researchers examined the impact of 3 antihypertension drugs...

10/04/2017

October 2024

Current Issue

October 2024

Volume 64

Issue 9